Stonebridge Financial Group LLC Increases Position in DexCom, Inc. (NASDAQ:DXCM)

Stonebridge Financial Group LLC lifted its position in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) by 944.5% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 3,217 shares of the medical device company's stock after purchasing an additional 2,909 shares during the period. Stonebridge Financial Group LLC's holdings in DexCom were worth $220,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. Private Trust Co. NA boosted its position in shares of DexCom by 266.3% during the 4th quarter. Private Trust Co. NA now owns 337 shares of the medical device company's stock worth $26,000 after acquiring an additional 245 shares in the last quarter. Golden State Wealth Management LLC raised its position in shares of DexCom by 211.2% during the 1st quarter. Golden State Wealth Management LLC now owns 389 shares of the medical device company's stock worth $27,000 after acquiring an additional 264 shares in the last quarter. Optiver Holding B.V. purchased a new stake in DexCom during the fourth quarter worth approximately $33,000. TD Private Client Wealth LLC boosted its holdings in DexCom by 62.8% in the fourth quarter. TD Private Client Wealth LLC now owns 433 shares of the medical device company's stock valued at $34,000 after purchasing an additional 167 shares in the last quarter. Finally, Larson Financial Group LLC boosted its holdings in DexCom by 40.5% in the fourth quarter. Larson Financial Group LLC now owns 475 shares of the medical device company's stock valued at $37,000 after purchasing an additional 137 shares in the last quarter. 97.75% of the stock is owned by hedge funds and other institutional investors.

DexCom Stock Up 1.5%

Shares of NASDAQ:DXCM opened at $86.33 on Monday. The company has a market cap of $33.85 billion, a price-to-earnings ratio of 64.43, a PEG ratio of 1.84 and a beta of 1.46. DexCom, Inc. has a fifty-two week low of $57.52 and a fifty-two week high of $117.19. The firm's 50-day simple moving average is $81.70 and its 200-day simple moving average is $79.59. The company has a quick ratio of 1.32, a current ratio of 1.50 and a debt-to-equity ratio of 0.55.

DexCom (NASDAQ:DXCM - Get Free Report) last announced its quarterly earnings data on Thursday, May 1st. The medical device company reported $0.32 earnings per share for the quarter, missing analysts' consensus estimates of $0.33 by ($0.01). DexCom had a net margin of 12.90% and a return on equity of 30.05%. The business had revenue of $1.04 billion during the quarter, compared to analysts' expectations of $1.02 billion. During the same period in the prior year, the firm posted $0.32 EPS. DexCom's revenue for the quarter was up 12.5% compared to the same quarter last year. As a group, equities research analysts predict that DexCom, Inc. will post 2.03 earnings per share for the current year.

Wall Street Analyst Weigh In

DXCM has been the topic of a number of research analyst reports. Canaccord Genuity Group raised their price objective on shares of DexCom from $103.00 to $106.00 and gave the stock a "buy" rating in a report on Friday, May 2nd. Mizuho initiated coverage on shares of DexCom in a research note on Thursday, April 10th. They set an "outperform" rating and a $85.00 price target on the stock. Barclays upped their price objective on shares of DexCom from $90.00 to $93.00 and gave the company an "equal weight" rating in a research note on Monday, May 5th. Piper Sandler dropped their price objective on DexCom from $100.00 to $90.00 and set an "overweight" rating on the stock in a report on Friday, May 2nd. Finally, Truist Financial began coverage on DexCom in a report on Monday, June 16th. They issued a "buy" rating and a $102.00 target price for the company. Five investment analysts have rated the stock with a hold rating, fifteen have issued a buy rating and three have given a strong buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $98.50.

Insider Activity at DexCom

In other DexCom news, EVP Sadie Stern sold 6,184 shares of the stock in a transaction dated Tuesday, May 27th. The shares were sold at an average price of $85.11, for a total value of $526,320.24. Following the completion of the transaction, the executive vice president now directly owns 109,621 shares of the company's stock, valued at approximately $9,329,843.31. This trade represents a 5.34% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, EVP Michael Jon Brown sold 10,000 shares of the business's stock in a transaction that occurred on Friday, May 23rd. The stock was sold at an average price of $84.28, for a total value of $842,800.00. Following the sale, the executive vice president now directly owns 95,602 shares in the company, valued at $8,057,336.56. This trade represents a 9.47% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 25,724 shares of company stock worth $2,157,034 over the last three months. 0.32% of the stock is currently owned by corporate insiders.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.